FTM
ELVN icon

First Turn Management’s Enliven Therapeutics ELVN Stock Holding History

First Turn Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.4M Buy
954,360
+330,521
+53% +$14M 5.18% 4
2026
Q1 		$24.5M Buy
+623,839
New +$17.3M 2.73% 15
2025
Q4 		– Sell
-783,411
Closed -$16M – 37
2025
Q3 		$16M Buy
783,411
+273,424
+54% +$5.51M 2.41% 19
2025
Q2 		$10.2M Sell
509,987
-25,105
-5% -$475K 1.91% 25
2025
Q1 		$10.5M Hold
535,092
– – 2.12% 25
2024
Q4 		$12M Hold
535,092
– – 2.16% 22
2024
Q3 		$13.7M Buy
535,092
+121,849
+29% +$2.82M 2.16% 26
2024
Q2 		$9.66M Buy
+413,243
New +$8.7M 1.57% 34

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

First Turn Management's ELVN Position: Q2 2026 in Review

First Turn Management increased its Enliven Therapeutics (ELVN) stake by 53% in Q2 2026, buying an estimated $14M and bringing the position to 954,360 shares worth $48.4M. The position accounts for 5.18% of the portfolio, ranked #4.

First Turn Management first reported a position in ELVN in Q2 2024 and has held it in 8 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • First Turn Management held 954,360 shares of Enliven Therapeutics worth $48.4M as of Q2 2026.
  • First Turn Management bought 330,521 Enliven Therapeutics shares in Q2 2026, an estimated $14M.
  • Enliven Therapeutics made up 5.18% of First Turn Management's portfolio in Q2 2026, its #4 holding.
  • First Turn Management first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on First Turn Management's 13F filing for Q2 2026, filed 14 Aug 2026.